Understand the source comparison
Cartalax vs Thymalin: Research Protocol Comparison
Peptide Structure Tripeptide (Ala-Glu-Asp), 290 Da Polypeptide complex, 3,000–5,000 Da Cartalax's smaller size simplifies synthesis and quality control; Thymalin's heterogeneity complicates standardization Primary Target Tissue Skeletal muscle (myocytes, satel
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Peptide Structure
- Tripeptide (Ala-Glu-Asp), 290 Da
- Polypeptide complex, 3,000–5,000 Da
- Cartalax's smaller size simplifies synthesis and quality control; Thymalin's heterogeneity complicates standardization
- Primary Target Tissue
- Skeletal muscle (myocytes, satellite cells)
- Thymus gland (thymic epithelial cells, thymocytes)
- No functional overlap. Entirely distinct organ systems
- Mechanism of Action
- Chromatin binding, transcription factor modulation (MyoD, myogenin upregulation)
- Thymic epithelial receptor activation, T-cell maturation signaling (IL-2/IL-7 pathway)
- Both involve gene expression changes, but at different cellular targets
- Typical Dosing Range
- 0.1–1.0 mg per dose (10–100 mcg/kg in rodents)
- 1–10 mg per dose (varies by polypeptide fraction concentration)
- Thymalin requires higher absolute doses due to multi-fraction composition
- Administration Route
- Subcutaneous or intramuscular injection
- Intramuscular injection preferred over subcutaneous
- Parenteral route mandatory for both; oral bioavailability negligible
- Duration of Effect
- Transcriptional changes persist 48–72 hours post-dose
- Immunomodulatory effects accumulate over 7–14 day treatment courses
- Cartalax shows per-dose efficacy; Thymalin requires cumulative dosing
- Storage Requirements
- Lyophilized powder at −20°C; reconstituted solution at 2–8°C, use within 14 days
- Lyophilized powder at −20°C; reconstituted solution at 2–8°C, use within 7 days
- Thymalin's peptide heterogeneity increases degradation risk post-reconstitution
- Primary Research Context
- Sarcopenia models, muscle regeneration, disuse atrophy
- Immune senescence, thymic involution, T-cell dysfunction
- Select based on target organ system. Not interchangeable